Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Dec;8(1):e001077.
doi: 10.1136/bmjresp-2021-001077.

Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study

Bradley E Chipps  1 , Frank C Albers  2 , Laurence Reilly  3 , Eva Johnsson  4 , Christy Cappelletti  5 , Alberto Papi  6
Affiliations
Clinical Trial

Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study

Bradley E Chipps et al. BMJ Open Respir Res. 2021 Dec.

Abstract

Introduction: Uncontrolled asthma is associated with substantial morbidity. While fast-acting bronchodilators provide quick relief from asthma symptoms, their use as rescue fails to address the underlying inflammation. Combining a short-acting beta2-agonist, such as albuterol (salbutamol), with an inhaled corticosteroid, such as budesonide, in a single inhaler as rescue therapy could help control both bronchoconstriction and inflammation, and reduce the risk of asthma exacerbations.

Methods and analysis: The Phase 3 MANDALA study was designed to determine the efficacy of albuterol in combination with budesonide (albuterol/budesonide 180/160 µg or 180/80 µg, two actuations of 90/80 µg or 90/40 µg, respectively) versus albuterol (180 µg, two actuations of 90 µg) as rescue therapy in adult, adolescent and paediatric patients with moderate-to-severe asthma. This event-driven study enrolled symptomatic patients (3000 adults/adolescents and 100 children aged 4-11 years) who experienced ≥1 severe asthma exacerbation in the previous year and were receiving maintenance therapy for ≥3 months prior to study entry. The primary efficacy endpoint was time-to-first severe asthma exacerbation.

Ethics and dissemination: The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice and the applicable regulatory requirements.

Trial registration: NCT03769090.

Keywords: asthma; asthma in primary care; paediatric asthma.

PubMed Disclaimer

Conflict of interest statement

Competing interests: BEC is an advisor for, has received consultancy fees from, and is on the speakers’ bureau for AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Regeneron and Sanofi Genzyme. FCA is an employee of Avillion. LR was an employee of Avillion when the study was conducted. EJ and CC are employees of AstraZeneca. AP reports grants, personal fees, non-financial support and other from GlaxoSmithKline, Boehringer Ingelheim, Chiesi Farmaceutici, TEVA, grants, personal fees and non-financial support from AstraZeneca and Menarini, personal fees, non-financial support and other from Mundipharma, Zambon, Novartis and Sanofi/Regeneron, personal fees from Roche and Edmondpharma and grants from Fondazione Maugeri and Fondazione Chiesi, outside the submitted work.

Figures

Figure 1
Figure 1
Study design. aTwo inhalations albuterol/budesonide pMDI 90/40 µg. bTwo inhalations albuterol/budesonide pMDI 90/80 µg. cTwo inhalations albuterol pMDI 90 µg. The screening/enrolment period was 2–4 weeks except if a severe exacerbation occured during this time, in which case it was ≤9 weeks. During screening, patients discontinued their usual rescue medication and used as-needed albuterol sulfate 180 µg. E, enrolment; EOT, end of treatment; FU, follow-up; pMDI, pressurised metered-dose inhaler; SABA, short-acting beta2-agonists; V, visit.
See this image and copyright information in PMC

References

    1. Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr 2019;7:246. 10.3389/fped.2019.00246 - DOI - PMC - PubMed
    1. Pearce N, Aït-Khaled N, Beasley R, et al. . Worldwide trends in the prevalence of asthma symptoms: phase III of the International study of asthma and allergies in childhood (ISAAC). Thorax 2007;62:758–66. 10.1136/thx.2006.070169 - DOI - PMC - PubMed
    1. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014;24:14009. 10.1038/npjpcrm.2014.9 - DOI - PMC - PubMed
    1. McCracken JL, Veeranki SP, Ameredes BT, et al. . Diagnosis and management of asthma in adults: a review. JAMA 2017;318:279–90. 10.1001/jama.2017.8372 - DOI - PubMed
    1. National Institute for Health (NIH), National Heart, Lung, and Blood Institute . Expert panel report 3: guidelines for the diagnosis and management of asthma (EPR-3), 2007. Available: www.nhlbi.nih.gov/guidelines/asthma

Publication types

Associated data